Wungki Park, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor of Medicine at Weill Cornell Medicine, shared a post on LinkedIn:
“Setidegrasib first-in-human KRAS G12D protein degrader with an early important momentum in KRAS therapeutic landscape
Early science:
plasma AUC – tumor G12D protein degradation – increased clinical response – early major molecular response by ctDNA
Monotherapy in 2/3L+ mPDAC: ORR 24% and clean safety profile (no GI, rash or BM tox) – Combinability
Early combination (mFOLFIRINOX) in 1L mPDAC: ORR 58%, 7/12 responses.
Science – clinical translation – science”
More posts featuring Wungki Park.
